Tanabe Pharma Amide Compound, BET Proteolysis, Cancer
Summary
European Patent Office published application EP3819305A1 for Tanabe Pharma Corporation on April 15, 2026, covering amide compounds with BET proteolysis-inducing action and their medicinal applications for cancer treatment, including leukemia and lymphoma. The patent application includes ten named inventors and carries IPC classifications spanning pharmaceutical compositions (A61K 38/05), therapeutic uses (A61P 35/00, A61P 35/02, A61P 43/00), and chemical compound structures (C07D 495/14, C07K 5/062, C07K 5/065). The publication designates 32 European states including Germany, France, the United Kingdom, and Switzerland.
About this source
GovPing monitors EPO Patent Bulletin - Therapeutics (A61P) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 24 changes logged to date.
What changed
European Patent Office published application EP3819305A1 for Tanabe Pharma Corporation covering amide compounds designed to induce BET (Bromodomain and Extra-Terminal motif) protein degradation and their medicinal applications. The invention targets cancer treatment including leukemia and lymphoma through proteolysis-targeting chimera (PROTAC) mechanisms. The publication creates prior art establishing the April 15, 2026 publication date, which determines patent term calculations and provides provisional rights during examination.
Pharmaceutical companies developing targeted protein degradation therapies should review this publication for freedom-to-operate considerations, particularly those working on BET inhibitors or related oncology programs. Competitors in the PROTAC or molecular glue space for hematological malignancies should assess potential overlap with their own development pipelines.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
AMIDE COMPOUND HAVING BET PROTEOLYSIS-INDUCING ACTION AND MEDICINAL APPLICATION THEREOF
Publication EP3819305A1 Kind: A1 Apr 15, 2026
Applicants
Tanabe Pharma Corporation
Inventors
YAMAZAKI, Ryuta, IBUKI, Tatsuya, SAWAGUCHI, Yuichi, OHBA, Kiyomi, HAMADA, Maiko, NIWA, Yasuki, ISHIDA, Yuko, MARUYAMA, Hideto, MATSUKI, Shiki, TANAKA, Minoru
IPC Classifications
A61K 38/05 20060101AFI20220225BHEP A61P 35/00 20060101ALI20220225BHEP A61P 35/02 20060101ALI20220225BHEP A61P 43/00 20060101ALI20220225BHEP C07D 495/14 20060101ALI20220225BHEP C07K 5/062 20060101ALI20220225BHEP C07K 5/065 20060101ALI20220225BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Parties
Related changes
Get daily alerts for EPO Patent Bulletin - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from EPO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when EPO Patent Bulletin - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.